Form 4: Plus Therapeutics Director Acquires Stock Options

Director Richard J. Hawkins acquired stock options in Plus Therapeutics, Inc. on February 18, 2025.

Summary

• Richard J. Hawkins, a director of Plus Therapeutics, Inc., filed a Form 4 on February 20, 2025.
• The filing reports a transaction that occurred on February 18, 2025, where Hawkins acquired 40,122 stock options with an exercise price of $1.18.
• These options vest monthly over 12 months from the grant date, or in full at the 2026 Annual Stockholder Meeting, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which can be seen as a positive sign of alignment between management and shareholders, but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, stock options, beneficial ownership, Richard J. Hawkins, Plus Therapeutics, director